Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

NexgenRx Inc. (V:NXG)

Business Focus: Investment Management & Fund Operators (NEC)

Dec 20, 2023 05:30 pm ET
NexgenRX Announces Declaration of Dividend
TORONTO, ON / ACCESSWIRE / December 20, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before January 4, 2024 to all shareholders of record as at the close of business on December 29, 2023. As of the date of this press release, there are a total of 70,531,195 common shares and 6,600,000 series 1 preferred shares issued and ou
Nov 23, 2023 05:20 pm ET
NexgenRx Inc. Announces Q3 2023 Quarterly Results with Continued Revenue Growth and Positive EBITDA
TORONTO, ON / ACCESSWIRE / November 23, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2023, with continued revenue growth to $3,390,174 for the quarter and $10,272,578 year to date. The quarterly revenue growth represents an increase of 8.86% over the same quarter in 2022. Year-to-date EBITDA is $1,020,591.
Aug 21, 2023 04:35 pm ET
Nexgenrx Announces Q2 2023 Quarterly Results (With Continued Revenue Growth), Consulting Agreement and Option Grant
TORONTO, ON / ACCESSWIRE / August 21, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the second quarter ended June 30, 2023, with continued revenue growth to $3,423,785 for the quarter and $6,882,404 year to date. The quarterly revenue growth represents an increase of $310,583 (or 9.98%) over the same quarter in 2022. The Company also announces the entering into of a consulting agreement with PBM Management Services (and the issuance of share compensation thereunder) and the grant
Jun 16, 2023 07:53 pm ET
TSX Venture Exchange Stock Maintenance Bulletins
VANCOUVER, BC, June 16, 2023 /CNW/ -
Jun 15, 2023 05:55 pm ET
NexgenRx Announces Declaration of Dividend
TORONTO, ON / ACCESSWIRE / June 15, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding.
May 18, 2023 08:10 pm ET
NexgenRx Announces Q1 2023 Quarterly Results with Continued Revenue Growth and Positive EBITDA and Announces Election of New Director
TORONTO, ON / ACCESSWIRE / May 18, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the first quarter ended March 31, 2023, with revenues growing to $3,458,619, an increase of $284,743 (or 8.97%) over the same quarter in 2022. The Company's cash position also remained strong at $1,264,334. The Company also held its annual and special meeting of shareholders today, at which all proposed resolutions were approved, including the election of a new director, Mr. Dave Bennett.
Apr 06, 2023 08:15 pm ET
NexgenRx Announces 2022 Year End Results With Continued Revenue Growth And Positive EBITDA
TORONTO, ON / ACCESSWIRE / April 6, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2022, once again highlighted by continued revenue growth and positive EBIDTA. The Company showed revenue growth of $939,942 in 2022 or 7.94% over the prior year, with a positive EBITDA of $1,626,524. The Company's cash position remained strong at $1,766,891, after total cash dividend payouts of $703,358 to the common shareholders.
Nov 29, 2022 07:30 pm ET
NexgenRx Announces Q3 2022 Financial Results with Continued Revenue Growth, Positive EBITDA and Free Cash Flow
TORONTO, ON / ACCESSWIRE / November 29, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2022, highlighted by continued revenue growth, positive EBIDTA and increased free cash flow. During Q3 2022, the Company showed revenue growth of 15.81% over the same period last year. Revenue for the third quarter was $3,317,358 and $9,401,460 year-to-date. The Company continued to achieve a positive EBITDA of $280,638 and shareholder free cash flow in Q3 2022. EBITDA in Q3
Sep 23, 2022 04:00 pm ET
Nexgenrx Announces Declaration Of Dividend
TORONTO, ON / ACCESSWIRE / September 23, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before October 10, 2022 to all shareholders of record as at the close of business on October 3, 2022. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and ou
Aug 18, 2022 06:25 pm ET
NexgenRx Announces Q2 2022 Financial Results with Continued Revenue Growth, Positive EBITDA and Increased Free Cash Flow
TORONTO, ON / ACCESSWIRE / August 18, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the second quarter ended June 30, 2022, highlighted by continued revenue growth, positive EBIDTA and increased free cash flow. The Company's Q2 revenue was 12.73% higher compared to the same period last year. Revenue for the second quarter was $3,113,202 and $6,287,078 year to date. The Company achieved positive EBITDA of $405,907 and shareholder free cash flow. In Q2, the Company generated increased free cash flo
May 17, 2022 05:35 pm ET
Nexgenrx Announces Q1 2022 Financial Results with Continued Growth in Net Income, EBIDTA and Revenue
TORONTO, ON / ACCESSWIRE / May 17, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") (TSXV:NXG) is pleased to announce its interim financial results for the first quarter ended March 31, 2022, highlighted by continued net income, EBITDA and revenue growth, with the Company's net income and EBITDA for the quarter being $377,956 and $753,368 respectively, increases of $15,845 and $59,669 over Q1 2021. Similarly, Q1 revenue was 13.22% higher compared to the same period last year.
Mar 25, 2022 08:10 pm ET
NexgenRx Announces 2021 Year End Results with Significant Revenue Growth and $3.5m EBITDA
TORONTO, ON / ACCESSWIRE / March 25, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the year ended December 31, 2021, highlighted by 12.01% revenue growth and EBITDA for the year of $3,503,957.
Jan 20, 2022 11:45 am ET
NexgenRx Announces Declaration of Dividend
TORONTO, ON / ACCESSWIRE / January 20, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on February 4, 2022 to all shareholders of record as at the close of business on January 28, 2022. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding.
Nov 19, 2021 11:35 am ET
NexgenRx Announces Financial Results for Q3 2021 with Increased Positive EBITDA and Free Cash Flow
TORONTO, ON / ACCESSWIRE / November 19, 2021 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2021. Despite the continuing uncertainties resulting from the COVID-19 pandemic, the Company continued to generate increased positive EBITDA and free cash flow; operated effectively and safely through the pandemic, lowered costs, and finished the quarter with continued increase in sales.
Aug 24, 2021 05:00 pm ET
NexgenRx Announces Expansion of Leadership Team
Addition of two senior executives, John Gray and Mark Payne to the leadership team signals continued focus on technology operations and strategic innovation partnerships
Aug 18, 2021 09:35 pm ET
NexgenRx Announces Financial Results for Q2 2021 With Continued Growth in Revenues and Adjusted EBITDA
TORONTO, ON / ACCESSWIRE / August 18, 2021 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the second quarter ended June 30, 2021, which continue to build upon the Company's positive 2020 year-end and Q1 2021 results. Despite the continued lockdowns due to COVID-19 throughout the second quarter, the Company's Q2 revenue was $2,761,544, an increase of $356,305 (14.8%) compared to the same period in 2020. Gross profit for Q1 2021 was $2,223,737, an increase of $97,440 compared to Q1 2020. The C
Jun 10, 2021 06:00 pm ET
NexgenRx Announces Annual Meeting Results
TORONTO, ON / ACCESSWIRE / June 10, 2021 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the results of its annual and special meeting (the "Meeting") of shareholders, which was held on Thursday, June 10, 2021. The Meeting was held, in part, to deliver the annual financial statements and related management's discussion and analysis of the Company, fix and appoint the directors of the Company, appoint the Company's auditors and approve the Company's Stock Option Plan, all as more particularly set out in the Management Informati
May 26, 2021 08:00 pm ET
NexgenRx Announces Financial Results for Q1 2021 with Continued EBITDA and Net Profit Growth
TORONTO, ON / ACCESSWIRE / May 26, 2021 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the first quarter ended March 31, 2021, which continue to build upon the Company's 2020 results, which showed record growth in both EBITDA and net profit. For Q1 2021, the Company recorded EBITDA of $693,699, representing an increase of $103,806 over same prior year period and continuing the positive trend from 2020. In spite of the COVID-19 lockdown in Ontario, the Company saw only a slight drop of $71k in reve
Mar 31, 2021 08:55 pm ET
NexgenRx Announces 2020 Year End Results with Record EBITDA and Net Profit
TORONTO, ON / ACCESSWIRE / March 31, 2021 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the year ended December 31, 2020, which show record growth in both EBITDA and net profit. The Company recorded EBITDA for the year of $3,035,108, representing an increase of $2,048,139 over the prior year. Total revenue increased by $1,501,355 or 15.7%, as compared to the prior year.
Mar 05, 2021 06:55 pm ET
NexgenRx Announces Retirement of all CBA/MYB Outstanding Indebtedness and Stock Option Grants
TORONTO, ON / ACCESSWIRE / March 5, 2021 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce that it has completed payment of all deferred consideration in connection with its previous acquisitions of Canadian Benefit Administrators Ltd. ("CBA") and MyBenetech Inc. ("MYB") (see the Company's press release dated July 24, 2018 for details). NexgenRx previously acquired all of the issued and outstanding shares of each of CBA and MYB for an aggregate purchase price of $4,000,000, with $2,800,000 having been paid upon cl
Nov 19, 2020 08:15 pm ET
NexgenRx Announces Q3 2020 Results
TORONTO, ON / ACCESSWIRE / November 19, 2020 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the third quarter ended September 30, 2020. Revenues of $2,651,682 were generated during the period, resulting in net income of $509,843 and EBITDA of $795,169, which represented increases of $728,561 and $674,126, respectively, over the third quarter of the prior year.
Aug 20, 2020 07:45 pm ET
NexgenRx Announces 2020 Q2 Interim Results
TORONTO, ON / ACCESSWIRE / August 20, 2020 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the quarter ended June 30, 2020.
Jul 09, 2020 07:30 pm ET
NexgenRx Announces Amendment of Share Capital, Creation and Issuance of Series 1 Preferred Shares
TORONTO, ON / July 9, 2020 / ACCESSWIRE / NEXGENRX INC. (TSXV:NGX) ("NexgenRx" or the "Corporation") is pleased to announce that it has given effect to the amendment of its share capital, as approved at the annual meeting of shareholders on May 27, 2020, with the removal of its previous five (5) classes of preferred shares and the replacement thereof with a single class of preferred shares, issuable in series. The directors have also approved the creation of a first series of preferred shares (the "Series 1 Preferred Shares"), which have the following attri
May 11, 2020 07:10 pm ET
NexgenRx Announces 2020 Q1 Interim Results
TORONTO, ON / ACCESSWIRE / May 11, 2020 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the quarter ended March 31, 2020.
Apr 09, 2020 07:10 pm ET
NexgenRx Announces 2019 Annual Results
TORONTO, ON / ACCESSWIRE / April 9, 2020 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the year ended December 31, 2019.
Nov 21, 2019 07:00 pm ET
NexgenRx Announces Q3 2019 Results
TORONTO, ON / ACCESSWIRE / November 21, 2019 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its Q3 2019 financial results.
Oct 11, 2019 07:00 pm ET
NexgenRx Announces Debt Re-Structuring
TORONTO, ON / ACCESSWIRE / October 11, 2019 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce that it has restructured its outstanding secured indebtedness. In particular, it has repaid $1,250,000 of its previously announced secured loan in the aggregate principal amount of $1,750,000, which it had obtained from an arm's length shareholder in connection with the Company's acquisitions announced last year (see the Company's press release dated July 24, 2018). The foregoing lender has agreed to amend and extend its secured loan
Aug 16, 2019 12:18 pm ET
NexgenRx Announces Q2 2019 Results
TORONTO, ON / ACCESSWIRE / August 16, 2019 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its Q2 2019 results, with the quarter continuing to provide positive revenue growth.
Jul 05, 2019 04:30 pm ET
NexgenRx Announces Director Retirement
Ronald C. LoucksNexgenRx Inc.President and CEO
May 29, 2019 11:55 pm ET
NexgenRx Announces Q1 2019 Financials and Annual Meeting Results
TORONTO, ON / ACCESSWIRE / May 29, 2019 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its Q1 2019 financial results and the results of its annual meeting of shareholders.
Apr 08, 2019 08:00 pm ET
NexgenRx Announces 2018 Year End Results
TORONTO, ON / ACCESSWIRE / April 8, 2019 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its 2018 year end results. The 2018 fiscal year was a very positive and transformational one for the Company, with revenue having increased by 26% (from $5.67 million in 2017 to $7.17 million in 2018). The year was highlighted by the acquisition of Canadian Benefit Administrators Ltd. ("CBA") and My Benetech Inc. ("MBT"), which was completed in July 2018. One-time acquisition related costs and other non-cash expenses relative to
Dec 06, 2018 06:45 pm ET
NexgenRX Announces Option Grants
TORONTO, ON / ACCESSWIRE / December 6, 2018 / NEXGENRX INC. ("NexgenRx" or the "Company") announces the grant to certain directors, officers and employees of NexgenRx of an aggregate of 2,700,000 options to acquire common shares in the capital of NexgenRx at a price of $0.25 for a period of 10 years. 1,700,000 of the foregoing options shall vest as to 33.3% each year for three years, beginning on the first anniversary of the grant date. The remaining 1,000,000 of the foregoing options shall vest immediately upon the Corporation's transaction and administrat
Oct 11, 2018 04:58 pm ET
NexgenRx Announces Completion of $425,000 Equity Financing
Toronto, Ontario (FSCwire) - NEXGENRX INC. ("NexgenRx" or the "Corporation") announces the completion of a private placement financing, pursuant to which it has issued an aggregate of 1,700,000 common shares of the Corporation (each, a "Common Share") at a price of $0.25 per Common Share for aggregate gross proceeds of $425,000.  The proceeds of this offering will be used to fund future technology, product and software development, as well as to provide general working capital for 2018.  Four-month hold periods apply to the securities issued under this offering (expiring February 12, 2019) in accordance with applicable securities laws.  Four insiders participated in the offering, acquiring an aggregate of 400,000 Common Shares.  The foregoing subscriptions are considered to be related party transactions and are therefore subject to the provisions of Multilateral Instrument 61-101 – "Protection of Minority Security Holders in Special Transactions", however exemptions are available from the minority shareholder approval and valuation requirements set forth in the foregoing Multilateral Instrument.
Aug 22, 2018 09:00 am ET
NexgenRx Announces New Director Appointment
Toronto, Ontario (FSCwire) - NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the appointment of Randy McGlynn to its Board of Directors effective immediately.
Aug 21, 2018 10:00 pm ET
NexgenRx Announces Q2 2018 Results
Toronto, Ontario (FSCwire) - NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its Q2 2018 financial results.
Aug 15, 2018 05:39 pm ET
NexgenRx Announces Completion of Acquisition of Two Benefit Administration Companies
Toronto, Ontario (FSCwire) - NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that it has it has completed its previously announced acquisition of two benefits administration companies, Canadian Benefit Administrators Ltd. ("CBA") and My Benetech Inc. ("MBT").  CBA is a Third Party Administrator ("TPA") providing administrative services to plan advisors and other intermediaries who wish to provide their clients with eligibility, enrolment & billing functionality, independent of any one insurance carrier. CBA has a team of administrators providing this service on behalf of various plan sponsors.  MyBenetech provides a wholesale value-add SaaS (Software as a Service) platform to plan sponsors who have their own dedicated administrators wishing to have the independence from any one insurance carrier, as well as TPA's like NexgenRx.  Both organizations use the industry-leading "Vital Objects" software, as the software platform.
Jul 24, 2018 05:00 pm ET
NexgenRx Announces Agreement to Acquire Two Benefit Administration Companies
Toronto, Ontario (FSCwire) - NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that it has entered into a binding purchase agreement to acquire two benefits administration companies, Canadian Benefit Administrators Ltd. ("CBA") and My Benetech Inc. ("MBT").  CBA is a Third Party Administrator ("TPA") providing administrative services to plan advisors and other intermediaries who wish to provide their clients with eligibility, enrolment & billing functionality, independent of any one insurance carrier. CBA has a team of administrators providing this service on behalf of various plan sponsors.  MyBenetech provides a wholesale value-add SaaS (Software as a Service) platform to plan sponsors who have their own dedicated administrators wishing to have the independence from any one insurance carrier, as well as TPA's like NexgenRx.  Both organizations use the industry-leading "Vital Objects" software, as the software platform.
May 01, 2018 07:15 am ET
NexgenRx and CannTrust Partner to Provide Medical Cannabis Benefit Access and Real Time Adjudication Services to NexgenRx Plan Members
Toronto, Ontario (FSCwire) - NEXGENRX INC. ("NexgenRx" or the "Company", TSX-V: NXG) is pleased to announce that it has signed an exclusive agreement with CannTrust Inc. ("CannTrust®"), one of Canada's leading licensed producers of medical cannabis and a wholly-owned subsidiary of CannTrust Holdings Inc. ("CannTrust", TSX: TRST), to create a simple, seamless ordering process for NexgenRx plan members. The agreement is for an initial five (5) year renewable term.
Jun 16, 2017 05:17 pm ET
NexgenRx Announces Annual Meeting Results
NEXGENRX INC. (TSX VENTURE: NXG) ("NexgenRx" or the " Company ") is pleased to announce that all ordinary and special resolutions were passed at the Annual and Special Meeting of Shareholders, which was held today in Toronto, Ontario. An aggregate of 38,626,359 (64.28%) of the outstanding shares of the Company entitled to be voted at the meeting were represented in person or by proxy. The following five nominees were elected as Directors of the Company to serve until the next annual meeting of shareholders of the Company, or until their successors are elected or
Jun 16, 2017 05:17 pm ET
NexgenRx Announces Annual Meeting Results
NEXGENRX INC. (TSX VENTURE:NXG) ("NexgenRx" or the " Company ") is pleased to announce that all ordinary and special resolutions were passed at the Annual and Special Meeting of Shareholders, which was held today in Toronto, Ontario. An...
May 15, 2017 08:18 pm ET
NexgenRx Announces Q1 2017 Results
NEXGENRX INC. (TSX VENTURE:NXG) ("NexgenRx" or the "Company") is pleased to announce its Q1 2017 financial results. Revenue for the quarter was $1,504,926, an increase of 7% over the same period last year. At the end of the first quarter,...
May 15, 2017 08:18 pm ET
NexgenRx Announces Q1 2017 Results
NEXGENRX INC. (TSX VENTURE: NXG) ("NexgenRx" or the "Company") is pleased to announce its Q1 2017 financial results.
Mar 31, 2017 06:45 pm ET
NexgenRx Announces 2016 Annual Results
NEXGENRX INC. ("NexgenRx" or the "Company") (TSX VENTURE:NXG) is pleased to announce its 2016 annual financial results. Revenues continued to grow during the year ended December 31, 2016. After experiencing revenue growth of 11% in...
Mar 31, 2017 06:45 pm ET
NexgenRx Announces 2016 Annual Results
NEXGENRX INC. ("NexgenRx" or the "Company") (TSX VENTURE: NXG) is pleased to announce its 2016 annual financial results.
Dec 05, 2016 05:03 pm ET
NexgenRx Announces CFO Changes
NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE: NXG) announces that Taba Merrikh has stepped down as CFO and the Board of Directors has unanimously appointed Kelly Ehler, CPA, CA, as Interim Chief Financial Officer, effective immediately. Mr. Ehler has extensive experience having served senior finance and operations roles in several private and TSX Listed Public Companies.
Dec 05, 2016 05:03 pm ET
NexgenRx Announces CFO Changes
NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE:NXG) announces that Taba Merrikh has stepped down as CFO and the Board of Directors has unanimously appointed Kelly Ehler, CPA, CA, as Interim Chief Financial Officer, effective...
Nov 14, 2016 05:24 pm ET
NexgenRx Announces Q3 2016 Results
NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE: NXG) announces Q3 revenue of $1,397,440 an increase of $208,895 over the same period last year. Gross profit for the quarter was $1,131,382 up $192,863 producing net quarterly income of $28,657, an increase of $146,852 over the same period last year.
Nov 14, 2016 05:24 pm ET
NexgenRx Announces Q3 2016 Results
NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE:NXG) announces Q3 revenue of $1,397,440 an increase of $208,895 over the same period last year. Gross profit for the quarter was $1,131,382 up $192,863 producing net quarterly income...
Jul 27, 2016 04:39 pm ET
NexgenRx Announces Q2 2016 Results
NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE: NXG) announces revenue of $1,565,891 an increase of $394,280 over the same period last year. Gross profit was $1,278,834 up $349,162 producing net quarterly income of $89,363. Revenue for the six months ended June 30, 2016 reached $2,977,820 or 25% higher than the same period last year.
Jul 27, 2016 04:39 pm ET
NexgenRx Announces Q2 2016 Results
NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE:NXG) announces revenue of $1,565,891 an increase of $394,280 over the same period last year. Gross profit was $1,278,834 up $349,162 producing net quarterly income of $89,363. Revenue...
Jun 03, 2016 06:15 pm ET
NexgenRx Announces New Directors
NEXGENRX INC. (TSX VENTURE: NXG) ("NexgenRx" or the "Corporation") announces the election of two new directors at its recently held annual and special meeting of its shareholders. Connie Graham of London, Ontario and Catherine Novick of Toronto, Ontario, were elected by shareholders to join incumbent directors Thomas Corcoran (Chairman), Ronald Loucks (President and Chief Executive Officer), David Rosenkrantz, Patrick Crowley and Barry Reiter as directors of the Corporation. All other matters presented to shareholders at the aforementioned meeting (including the approval
Jun 03, 2016 06:15 pm ET
NexgenRx Announces New Directors
NEXGENRX INC. (TSX VENTURE:NXG) ("NexgenRx" or the "Corporation") announces the election of two new directors at its recently held annual and special meeting of its shareholders. Connie Graham of London, Ontario and Catherine Novick of Toronto,...
May 24, 2016 04:18 pm ET
NexgenRx Announces Equitable Life as the Latest Carrier Signed to Their Provider Portal - theclaimsXchange.com®
NexgenRx Inc. ("NexgenRx" or the "Corporation") (TSX VENTURE:NXG) and Equitable Life of Canada® ("Equitable Life") are pleased to announce their agreement wherein NexgenRx will provide Equitable Life's plan members with a convenient new option...
May 24, 2016 04:18 pm ET
NexgenRx Announces Equitable Life as the Latest Carrier Signed to Their Provider Portal - theclaimsXchange.com®
NexgenRx Inc. ("NexgenRx" or the "Corporation") (TSX VENTURE: NXG) and Equitable Life of Canada(r) ("Equitable Life") are pleased to announce their agreement wherein NexgenRx will provide Equitable Life's plan members with a convenient new option for submitting paramedical and vision care claims in real time.
May 06, 2016 03:02 pm ET
NexgenRx Announces Special Provisions in Alberta for Plan Members Affected by the Fort McMurray Fires
NEXGENRX INC. (TSX VENTURE:NXG) ("NexgenRx" or the "Corporation") announces that it has immediately instituted special provisions to assist plan members affected by the Fort McMurray fires. Given the severity of the situation, NexgenRx will be...
May 06, 2016 03:02 pm ET
NexgenRx Announces Special Provisions in Alberta for Plan Members Affected by the Fort McMurray Fires
NEXGENRX INC. (TSX VENTURE: NXG) ("NexgenRx" or the "Corporation") announces that it has immediately instituted special provisions to assist plan members affected by the Fort McMurray fires. Given the severity of the situation, NexgenRx will be removing the "Refill Too Soon" edit check, allowing members to access their medications that were lost or abandoned. Members are urged to visit any location of their pharmacy chain who can access their prescription on file, which will then be filled and submitted for approval by NexgenRx. If that is not possible, members
Apr 26, 2016 12:56 pm ET
NexgenRx Announces Q1 2016 Results
NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE:NXG) announces revenue of $1,411,929 an increase of 17.5% over the same period last year. Gross profit was $1,133,731 up 17.3% producing net quarterly income of $47,843, compared with...
Apr 26, 2016 12:56 pm ET
NexgenRx Announces Q1 2016 Results
NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE: NXG) announces revenue of $1,411,929 an increase of 17.5% over the same period last year. Gross profit was $1,133,731 up 17.3% producing net quarterly income of $47,843, compared with $4,560 for the same period last year.
Mar 24, 2016 04:24 pm ET
NexgenRx Announces 2015 Annual Results
NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE: NXG) is pleased to announce its 2015 annual results.